COMMUNIQUÉS West-GlobeNewswire

-
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
17/04/2024 -
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
17/04/2024 -
Q1 2024 Revenue and Business Update
17/04/2024 -
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
17/04/2024 -
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
17/04/2024 -
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
17/04/2024 -
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
17/04/2024 -
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
17/04/2024 -
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
17/04/2024 -
Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en plaques
17/04/2024 -
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
17/04/2024 -
Health Advocate Applauds Federal Budget 2024 in providing costing on a National Pharmacare Plan; a milestone in universal free access to contraceptives
17/04/2024 -
Les professionnels de la santé des femmes applaudissent le budget fédéral 2024 incluant les coûts pour un Plan national d'assurance-médicaments; une étape importante vers un accès universel et gratuit à toutes les méthodes contraceptives
17/04/2024 -
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
17/04/2024 -
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
16/04/2024 -
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
16/04/2024 -
Panbela Announces Transfer to OTCQB Market
16/04/2024 -
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
16/04/2024 -
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
16/04/2024
Pages